Julie Behr
About Julie Behr
Julie Behr is a Data Scientist II at ROME Therapeutics, with a strong background in bioengineering and computational biology. She has contributed to significant advancements in cancer research and genomic analysis through her work and academic achievements.
Work at ROME Therapeutics
Julie Behr currently holds the position of Data Scientist II at ROME Therapeutics, a role she began in 2023. Previously, she worked at the same organization as a Data Scientist from 2021 to 2023. During her tenure, she contributed to the development of proprietary analysis pipelines and validated the ROMEquant platform, achieving significant cost savings. Her work involved collaboration with biologists and chemists to design experiments aimed at biomarker identification and drug discovery.
Education and Expertise
Julie Behr has an extensive educational background in bioengineering, computational biology, and mechanical engineering. She earned a Master of Science in Bioengineering from Penn State University in 2013. She pursued her Doctor of Philosophy in Computational Biology at Weill Cornell Graduate School of Medical Sciences from 2013 to 2021. Additionally, she completed a Bachelor of Science in Mechanical Engineering at Penn State University, also in 2013. This diverse academic foundation supports her expertise in data science and genomic analysis.
Background in Research
Julie Behr has a strong research background, having worked as a PhD Candidate in the Imielinski Lab at both Weill Cornell Medicine and the New York Genome Center from 2017 to 2021. During this period, she led the development of new pipelines to characterize LINE-1 activity in cancer using large-scale pan-cancer datasets. Her research focused on exploring the dark genome at the locus level through various sequencing technologies.
Achievements in Data Science
Throughout her career, Julie Behr has achieved notable accomplishments in the field of data science. She enabled a 30-fold cost savings by validating the ROMEquant platform and publicly available pipelines. Her leadership in developing analysis pipelines has advanced the understanding of genomic data, particularly in relation to cancer research. She has also collaborated with cross-functional teams to enhance biomarker identification and support drug discovery initiatives.